Welcome to our dedicated page for Exscientia Plc news (Ticker: EXAI), a resource for investors and traders seeking the latest updates and insights on Exscientia Plc stock.
Exscientia Plc (EXAI) is a pioneer in AI-driven drug discovery, transforming pharmaceutical research through automated small molecule design. This page serves as the definitive source for tracking the company's latest developments, offering investors and industry observers timely updates on its groundbreaking work.
Access comprehensive coverage of financial results, research milestones, and strategic partnerships that define Exscientia's progress. Our curated news collection includes press releases on clinical advancements, technology innovations, and regulatory developments essential for understanding the company's trajectory.
Key updates feature Exscientia's AI-optimized drug candidates, collaborations with leading pharmaceutical organizations, and insights into their automated discovery platform. The resource is particularly valuable for tracking how machine learning accelerates compound design while maintaining rigorous quality standards.
Bookmark this page for efficient monitoring of Exscientia's contributions to biopharmaceutical innovation. Return regularly to stay informed about how their AI-first approach continues to reshape drug development timelines and methodologies.
Exscientia announced positive results from its Phase 1 healthy volunteer study of EXS-21546, a selective A2A receptor antagonist. The study confirmed potency and selectivity with low CNS exposure, supporting a Phase 1b/2 study in patients with high adenosine signature solid tumors, anticipated to start in the second half of 2022. The trial showed dose-dependent effects and was well-tolerated, with only one serious adverse event recorded that resolved without intervention. These findings enhance the potential for EXS-21546 to improve immunomodulatory treatments in cancer therapy.
Exscientia (Nasdaq: EXAI) announced that Andrew Hopkins, CEO, and Dave Hallett, COO, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 9:20 a.m. PT. A live webcast will be accessible on the company's website, with an archived replay available for 30 days post-presentation. Exscientia is an AI-driven pharmatech company focused on revolutionizing drug discovery and development, with over 30 projects actively in progress, aiming to enhance patient outcomes through advanced treatment options.
Exscientia plc (NASDAQ: EXAI) reported a successful first quarter of 2022, achieving $9.2 million in revenue, up from $7.0 million in Q1 2021. The company has advanced its collaborations, notably with Sanofi and Bristol Myers Squibb, enhancing its AI-driven precision medicine capabilities. Exscientia ended the quarter with $719.8 million in cash, despite operational cash outflows of $10.4 million. Noteworthy progress includes the launch of Xcellomics™ and presentations at the AACR Annual Meeting, underscoring its leadership in AI-designed drug development.
Exscientia (NASDAQ: EXAI), an AI-focused pharmatech, will report its financial results for Q1 ended March 31, 2022, on
Rallybio Corporation (Nasdaq: RLYB) reported its Q1 2022 financial results, highlighting a net loss of $14.5 million, or $0.48 per share, compared to a net loss of $13.3 million in Q1 2021. The company initiated a Phase 1b study for RLYB212 targeting fetal and neonatal alloimmune thrombocytopenia (FNAIT) and continues its Phase 1 study of RLYB116. Rallybio also acquired RLYB331 from Sanofi, aimed at treating severe anemias. R&D expenses decreased to $7.6 million, while G&A expenses rose to $6.7 million. Cash reserves stand at $161.4 million.
Symbotic reported a 315% year-over-year revenue growth, reaching $96.3 million for Q2 FY2022, driven by increased system installations. Despite this, the company posted a net loss of $29.9 million and an adjusted EBITDA loss of $(26.2) million. Operating expenses rose due to preparations for public operations. The company also announced the appointment of Michael Loparco as CEO, aimed at enhancing operational scalability. Symbotic continues to grow its presence in warehouse automation, targeting Fortune 100 retailers.
Exscientia (Nasdaq: EXAI) announced that CFO Ben Taylor and CTO Garry Pairaudeau will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 5:20 p.m. P.T. A live webcast will be accessible on the Company’s website under the 'Investors & Media' section, with an archived replay available for 30 days post-event. Exscientia is an AI-driven pharmatech company focused on rapid drug discovery and development, with over 30 projects currently in progress aimed at improving patient outcomes.
Exscientia plc (Nasdaq: EXAI) announced its participation in the upcoming AACR Annual Meeting from April 8-13, 2022, in New Orleans. Exscientia's VP of Precision Medicine, Nikolaus Krall, emphasized the company's focus on enhancing its human tissue precision medicine platform and expanding research into breast and ovarian cancers. The company will present three posters showcasing AI-driven drug discovery capabilities and attend with a dedicated booth (#2016) to discuss its collaborations, including one with Xcellomics for early-stage drug discovery acceleration.
Exscientia plc (Nasdaq: EXAI) has appointed Michael Krams, M.D., as its new Chief Quantitative Medicine Officer. Dr. Krams will enhance the clinical development strategy for the company’s investigational medicines, utilizing patient-based models and AI-driven design. His experience includes leading a large team at Janssen R&D and advancing adaptive trial methodologies. The appointment aims to improve trial design and patient selection to maximize clinical success. Exscientia is focused on AI-driven drug discovery and has over 30 projects in its pipeline.
Symbotic LLC has appointed Michael J. Loparco as its new Chief Executive Officer, succeeding Rick Cohen, who will transition to Chief Product Officer. This leadership change aligns with Symbotic's plans to go public on Nasdaq through a merger with SVF Investment Corp. 3 (SVFC). The merger aims to facilitate Symbotic's growth in robotics and automation technology within supply chains. The completed business combination is contingent on shareholder approval and timely fulfilment of conditions outlined in the merger agreement.
FAQ
What is the current stock price of Exscientia Plc (EXAI)?
What is the market cap of Exscientia Plc (EXAI)?
